A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Launched by IDP DISCOVERY PHARMA S.L. · Jun 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IDP-121 for patients with certain types of blood cancers, including multiple myeloma, various forms of lymphoma, and chronic lymphocytic leukemia. The trial has two parts: the first part focuses on finding the highest dose of IDP-121 that patients can tolerate without serious side effects, while the second part looks at how well the treatment works in terms of patient responses, how long those responses last, and overall patient survival.

To be eligible for this trial, participants must be at least 18 years old and have specific types of blood cancers that are difficult to treat with standard therapies. Patients should also have a good general health status and be willing to follow the study guidelines. If you join the trial, you can expect to receive the new treatment and will be monitored closely for any effects it may have, both positive and negative. It’s important to know that participants can withdraw from the study at any time without it affecting their future medical care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years
• • 2. Performance status (ECOG) ≤ 2
• • 3. Life expectancy ≥3 months
• • 4. Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
• • 5. Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
• • 6. Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to reveive the available treatments.
• • 7. Adequate hematological or biochemical parameters as specified below
• • 1. Hemoglobin \> 8.0 g/dl (without transfusion support within 7 days)
• • 2. Platelets count \> 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L.
• • 3. Absolute neutrophil count (ANC) \> 0.75 x109/L (without G-CSF support within 7 days)
• • 4. Aspartate transaminase (AST): \<2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases)
• • 5. Alanine transaminase (ALT): \< 2.5 x the upper limit range (in patients with no liver metastases or \<5 x ULN in patients with liver metastases)
• • 6. Total bilirubin: \< 2 x the upper limit range.
• • 7. Calculated or measured creatinine clearance: \>30 mL/min (calculated from the Cockcroft-Gault formula).
• • 8. Left ventricular ejection fraction \> 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.
• Exclusion Criteria:
• • 1. Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade \<2 symptomatic peripheral neuropathy is allowed.
• • 2. Pregnant or lactating women; men and women of reproductive potential\* (as defined in the Appendix 2) who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence).
• • \*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.
• • 3. History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site)
• • 4. History of clinically significant hypotension.
• • 5. History of clinically significant allergic or hyper-sensitivity reactions.
• 6. History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to):
• • Thromboembolism
• • Peripheral arterial disease
• • Vasculitis
• 7. Other relevant diseases or adverse clinical conditions:
• • Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study.
• • Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months).
• • History of significant neurological or psychiatric disorders
• • 8. Clinically significant or active infection.
• • 9. Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
• • 10. The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels \<50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive).
• • 11. Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.
• • 12. Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
• • 13. Limitation of the patient's ability to comply with the treatment or follow-up protocol.
• • 14. If a COVID-19 vaccine is administered, it should be done \>72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase").